Met Life Investment Management, LLC Biocryst Pharmaceuticals Inc Transaction History

Met Life Investment Management, LLC

$18.1 Billion
Q1 2025

A detailed history of Met Life Investment Management, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Met Life Investment Management, LLC holds 121,918 shares of BCRX stock, worth $1.07 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

121,918

Previous 126,949 3.96%

Holding current value

$1.07 Million

Previous $954,000 4.19%

% of portfolio

0.01%

Previous 0.01%

44 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$7.06 - $9.39 $35,518 - $47,241	-5,031 Reduced 3.96%	121,918 $914,000
Q4 2024 Feb 13, 2025	BUY	$7.03 - $8.43 $50,608 - $60,687	7,199 Added 6.01%	126,949 $954,000
Q2 2024 Aug 13, 2024	BUY	$4.13 - $6.79 $127,121 - $208,996	30,780 Added 34.6%	119,750 $740,000
Q1 2024 May 14, 2024	BUY	$4.89 - $7.65 $435,063 - $680,620	88,970 New	88,970 $451,000
Q2 2023 Apr 29, 2024	BUY	$6.96 - $8.81 $677,632 - $857,750	97,361 New	97,361 $685,000
Q1 2023 May 09, 2024	BUY	$7.94 - $11.84 $773,046 - $1.15 Million	97,361 New	97,361 $812 Million
Q1 2022 May 10, 2024	BUY	$11.56 - $19.76 $1.13 Million - $1.92 Million	97,361 New	97,361 $1.58 Million
Q1 2022 Mar 22, 2023	BUY	$11.56 - $19.76 $408,611 - $698,456	35,347 Added 57.0%	97,361 $1.58 Million
Q1 2022 May 12, 2022	BUY	$11.56 - $19.76 $408,611 - $698,456	35,347 Added 57.0%	97,361 $1.58 Million
Q4 2021 Jun 21, 2023	SELL	$11.18 - $15.46 $395,179 - $546,464	-35,347 Reduced 36.31%	62,014 $858,000
Q3 2021 May 17, 2024	SELL	$14.21 - $17.65 $87,618 - $108,829	-6,166 Reduced 9.04%	62,014 $891,000
Q3 2021 Jun 21, 2023	SELL	$14.21 - $17.65 $502,280 - $623,874	-35,347 Reduced 36.31%	62,014 $891,000
Q3 2021 Mar 22, 2023	SELL	$14.21 - $17.65 $87,618 - $108,829	-6,166 Reduced 9.04%	62,014 $891,000
Q3 2021 Nov 15, 2021	SELL	$14.21 - $17.65 $87,618 - $108,829	-6,166 Reduced 9.04%	62,014 $891,000
Q2 2021 Jun 21, 2023	SELL	$9.5 - $17.24 $277,219 - $503,080	-29,181 Reduced 29.97%	68,180 $1.08 Million
Q1 2021 May 17, 2024	SELL	$7.37 - $13.61 $153,222 - $282,951	-20,790 Reduced 23.37%	68,180 $693,000
Q1 2021 Jun 26, 2023	SELL	$7.37 - $13.61 $215,063 - $397,153	-29,181 Reduced 29.97%	68,180 $693 Million
Q1 2021 Mar 22, 2023	SELL	$7.37 - $13.61 $34,417 - $63,558	-4,670 Reduced 6.41%	68,180 $693,000
Q1 2021 May 14, 2021	SELL	$7.37 - $13.61 $34,417 - $63,558	-4,670 Reduced 6.41%	68,180 $693,000
Q4 2020 May 24, 2024	BUY	$3.37 - $8.61 $9,331 - $23,841	2,769 Added 3.95%	72,850 $542,000
Q4 2020 Jun 22, 2023	SELL	$3.37 - $8.61 $82,602 - $211,039	-24,511 Reduced 25.18%	72,850 $542,000
Q4 2020 Mar 22, 2023	BUY	$3.37 - $8.61 $9,331 - $23,841	2,769 Added 3.95%	72,850 $542,000
Q4 2020 Feb 16, 2021	BUY	$3.37 - $8.61 $9,331 - $23,841	2,769 Added 3.95%	72,850 $543,000
Q3 2020 Jun 26, 2023	SELL	$3.43 - $5.53 $93,570 - $150,858	-27,280 Reduced 28.02%	70,081 $241,000
Q2 2020 May 24, 2024	SELL	$1.9 - $5.61 $35,889 - $105,967	-18,889 Reduced 21.23%	70,081 $334 Million
Q2 2020 Jun 26, 2023	SELL	$1.9 - $5.61 $51,832 - $153,040	-27,280 Reduced 28.02%	70,081 $333,000
Q2 2020 Mar 22, 2023	BUY	$1.9 - $5.61 $58,884 - $173,865	30,992 Added 79.29%	70,081 $333,000
Q2 2020 Aug 14, 2020	BUY	$1.9 - $5.61 $58,884 - $173,865	30,992 Added 79.29%	70,081 $334,000
Q1 2020 Jul 12, 2023	SELL	$1.6 - $4.11 $93,235 - $239,497	-58,272 Reduced 59.85%	39,089 $78,000
Q1 2020 Mar 22, 2023	SELL	$1.6 - $4.11 $50,176 - $128,889	-31,360 Reduced 44.51%	39,089 $78,000
Q1 2020 May 15, 2020	SELL	$1.6 - $4.11 $50,176 - $128,889	-31,360 Reduced 44.51%	39,089 $78,000
Q4 2019 Jul 12, 2023	SELL	$1.59 - $3.45 $42,790 - $92,846	-26,912 Reduced 27.64%	70,449 $243,000
Q4 2019 Mar 22, 2023	BUY	$1.59 - $3.45 $31,578 - $68,520	19,861 Added 39.26%	70,449 $243,000
Q4 2019 Feb 14, 2020	BUY	$1.59 - $3.45 $31,578 - $68,520	19,861 Added 39.26%	70,449 $243,000
Q3 2019 Jul 12, 2023	SELL	$2.5 - $3.73 $116,932 - $174,463	-46,773 Reduced 48.04%	50,588 $145,000
Q2 2019 Jul 12, 2023	SELL	$2.91 - $9.15 $136,109 - $427,972	-46,773 Reduced 48.04%	50,588 $191,000
Q1 2019 Jul 13, 2023	SELL	$7.38 - $9.72 $345,184 - $454,633	-46,773 Reduced 48.04%	50,588 $411,000
Q4 2018 Jul 13, 2023	SELL	$6.51 - $9.6 $304,492 - $449,020	-46,773 Reduced 48.04%	50,588 $408,000
Q4 2018 Mar 22, 2023	SELL	$6.51 - $9.6 $186,303 - $274,732	-28,618 Reduced 36.13%	50,588 $408,000
Q4 2018 Feb 14, 2019	SELL	$6.51 - $9.6 $186,303 - $274,732	-28,618 Reduced 36.13%	50,588 $408,000
Q3 2018 Jul 13, 2023	SELL	$5.52 - $7.99 $258,186 - $373,716	-46,773 Reduced 48.04%	50,588 $385,000
Q3 2018 Mar 22, 2023	SELL	$5.52 - $7.99 $100,215 - $145,058	-18,155 Reduced 18.65%	79,206 $604,000
Q3 2018 Nov 14, 2018	BUY	$5.52 - $7.99 $200,513 - $290,236	36,325 Added 84.71%	79,206 $604,000
Q4 2017 Feb 15, 2018	BUY	$4.16 - $5.33 $178,384 - $228,555	42,881	42,881 $211,000

Others Institutions Holding BCRX

# of Institutions

294

Shares Held

177M

Call Options Held

721K

Put Options Held

489K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.63B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Account

Met Life Investment Management, LLC Biocryst Pharmaceuticals Inc Transaction History